Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Nadolol does not increase depressive symptoms versus placebo in chronic aggression; confirms mood safety and supports further aggression trials.
Depressive symptoms were rated during a double-blind placebo-controlled trial of nadolol for chronic aggression. Depressive symptoms were not significantly different in nadolol and placebo groups during any phase of the drug trial.
No takes yet. Share an insight, caveat, or question.
Sorgi et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: